
Anna K L Reyners

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7984597/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Factors associated with cognitive impairment and cognitive concerns in patients with metastatic non-small cell lung cancer. Neuro-Oncology Practice, 2022, 9, 50-58.	1.6	4
2	Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data. Supportive Care in Cancer, 2022, 30, 5137-5146.	2.2	3
3	Experiences of patients and health care professionals on the quality of telephone follow-up care during the COVID-19 pandemic: a large qualitative study in a multidisciplinary academic setting. BMJ Open, 2022, 12, e058361.	1.9	10
4	Evidence- and consensus-based guidelines for drug-drug interactions with anticancer drugs; A practical and universal tool for management. Seminars in Oncology, 2022, 49, 119-129.	2.2	10
5	Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases. BMC Cancer, 2022, 22, 247.	2.6	3
6	Evaluating quality of care at the end of life and setting best practice performance standards: a population-based observational study using linked routinelyAcollected administrative databases. BMC Palliative Care, 2022, 21, 51.	1.8	7
7	A multicenter, dose-finding, phase 1b study of imatinib in combination with alpelisib as third-line treatment in patients with advanced gastrointestinal stromal tumor. BMC Cancer, 2022, 22, 511.	2.6	6
8	Self-reported taste and smell alterations and the liking of oral nutritional supplements with sensory-adapted flavors in cancer patients receiving systemic antitumor treatment. Supportive Care in Cancer, 2021, 29, 5691-5699.	2.2	11
9	The effect of treatment modifications by an onco-geriatric MDT on one-year mortality, days spent at home and postoperative complications. Journal of Geriatric Oncology, 2021, 12, 779-785.	1.0	15
10	OTHR-01. Unmet clinical needs in patients with brain metastases in the current treatment era. Neuro-Oncology Advances, 2021, 3, iii14-iii14.	0.7	0
11	Effects of supervised exercise during adjuvant endocrine therapy in overweight or obese patients with breast cancer: The I-MOVE study. Breast, 2021, 58, 138-146.	2.2	6
12	Taste, smell and mouthfeel disturbances in patients with gastrointestinal stromal tumors treated with tyrosine-kinase inhibitors. Supportive Care in Cancer, 2021, , 1.	2.2	5
13	Distress, problems, referral wish, andÂsupportive health care use inÂbreast cancer survivors beyond theÂfirst year after chemotherapy completion. Supportive Care in Cancer, 2020, 28, 3023-3032.	2.2	8
14	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. JAMA Network Open, 2020, 3, e1918939.	5.9	40
15	Risk factors of unmet needs among women with breast cancer in the postâ€treatment phase. Psycho-Oncology, 2020, 29, 539-549.	2.3	20
16	Comparison of Circulating Cell-Free DNA Extraction Methods for Downstream Analysis in Cancer Patients. Cancers, 2020, 12, 1222.	3.7	40
17	Clinical utility of circulating tumor DNA as a response and follow-up marker in cancer therapy. Cancer and Metastasis Reviews, 2020, 39, 999-1013.	5.9	38
18	Death Anxiety in Patients With Metastatic Non-Small Cell Lung Cancer With and Without Brain Metastases. Journal of Pain and Symptom Management, 2020, 60, 422-429.e1.	1.2	21

ANNA K L REYNERS

#	Article	IF	CITATIONS
19	Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Science Translational Medicine, 2020, 12, .	12.4	83
20	Dexamethasone for the Prevention of a Pain Flare After Palliative Radiation Therapy for Painful Bone Metastases: The Multicenter Double-Blind Placebo-Controlled 3-Armed Randomized Dutch DEXA Study. International Journal of Radiation Oncology Biology Physics, 2020, 108, 546-553.	0.8	12
21	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics Journal, 2019, 19, 473-479.	2.0	9
22	Survival and Cost-Effectiveness of Trabectedin Compared to Ifosfamide Monotherapy in Advanced Soft Tissue Sarcoma Patients. Sarcoma, 2019, 2019, 1-11.	1.3	1
23	How to incorporate geriatric assessment in clinical decision-making for older patients with cancer. An implementation study. Journal of Geriatric Oncology, 2019, 10, 951-959.	1.0	50
24	NCOG-03. COGNITIVE CONCERNS AND PERFORMANCE IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (mNSCLC). Neuro-Oncology, 2019, 21, vi159-vi159.	1.2	0
25	Therapeutic Drug Monitoring of Oral Anticancer Drugs: The Dutch Pharmacology Oncology Group–Therapeutic Drug Monitoring Protocol for a Prospective Study. Therapeutic Drug Monitoring, 2019, 41, 561-567.	2.0	33
26	Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA. Oncologist, 2019, 24, e387-e390.	3.7	5
27	Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clinical Cancer Research, 2018, 24, 3928-3940.	7.0	35
28	A systematic review of the effectiveness of patient-based educational interventions to improve cancer-related pain. Cancer Treatment Reviews, 2018, 63, 96-103.	7.7	87
29	Early Evaluation of Response Using 18F-FDG PET Influences Management in Gastrointestinal Stromal Tumor Patients Treated with Neoadjuvant Imatinib. Journal of Nuclear Medicine, 2018, 59, 194-196.	5.0	24
30	Outcome of Nonsurgical Management of Extra-Abdominal, Trunk, and Abdominal Wall Desmoid-Type Fibromatosis: A Population-Based Study in the Netherlands. Sarcoma, 2018, 2018, 1-8.	1.3	14
31	Feasibility of hospital-initiated non-facilitator assisted advance care planning documentation for patients with palliative care needs. BMC Palliative Care, 2018, 17, 79.	1.8	11
32	A single digital droplet PCR assay to detect multiple <i>KIT</i> exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors. Oncotarget, 2018, 9, 13870-13883.	1.8	28
33	Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options. Clinical Pharmacokinetics, 2017, 56, 683-688.	3.5	59
34	Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumourÂpatients. European Journal of Cancer, 2017, 76, 76-83.	2.8	32
35	Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 55, 16-25.	7.7	18
36	Central venous access related adverse events after trabectedin infusions in soft tissue sarcoma patients; experience and management in a nationwide multi-center study. Clinical Sarcoma Research, 2017, 7, 2.	2.3	8

ANNA K L REYNERS

#	Article	IF	CITATIONS
37	Metallic Taste in Cancer Patients Treated with Systemic Therapy: A Questionnaire-based Study. Nutrition and Cancer, 2017, 69, 140-145.	2.0	23
38	Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity – A retrospective multicentre study in a large cohort of GIST patients. European Journal of Cancer, 2017, 86, 318-325.	2.8	23
39	Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib. European Journal of Cancer, 2017, 86, 226-232.	2.8	13
40	Screening for psychological distress before radiotherapy for painful bone metastases may be useful to identify patients with high levels of distress. Acta Oncológica, 2017, 56, 1720-1727.	1.8	2
41	Web-Based Tailored Psychoeducation for Breast Cancer Patients at the Onset of the Survivorship Phase: AÂMulticenter Randomized Controlled Trial. Journal of Pain and Symptom Management, 2017, 54, 466-475.	1.2	43
42	Web-based information and support for patients with a newly diagnosed neuroendocrine tumor: a feasibility study. Supportive Care in Cancer, 2017, 25, 2075-2083.	2.2	11
43	Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapy. Clinical Nutrition, 2017, 36, 1642-1648.	5.0	41
44	Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature. Oncotarget, 2017, 8, 109836-109847.	1.8	8
45	Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer. PLoS ONE, 2016, 11, e0165385.	2.5	13
46	Don't forget the dentist: Dental care use and needs of women with breast cancer. Breast, 2016, 29, 1-7.	2.2	6
47	The palatability of oral nutritional supplements: before, during, and after chemotherapy. Supportive Care in Cancer, 2016, 24, 4301-4308.	2.2	25
48	Taste and smell function in testicular cancer survivors treated with cisplatin-based chemotherapy in relation to dietary intake, food preference, and body composition. Appetite, 2016, 105, 392-399.	3.7	13
49	Predictors of enduring clinical distress in women with breast cancer. Breast Cancer Research and Treatment, 2016, 158, 563-572.	2.5	20
50	Assessment of Estrogen Receptor Expression in Epithelial Ovarian Cancer Patients Using 16α- ¹⁸ F-Fluoro-17β-Estradiol PET/CT. Journal of Nuclear Medicine, 2015, 56, 50-55.	5.0	44
51	Internet-based support programs to alleviate psychosocial and physical symptoms in cancer patients: A literature analysis. Critical Reviews in Oncology/Hematology, 2015, 95, 26-37.	4.4	81
52	Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecologic Oncology, 2015, 138, 634-639.	1.4	43
53	A 21-Year-Old Patient With a HER2-Positive Colorectal Cancer. Gastroenterology, 2015, 148, 20-21.	1.3	5
54	Effect of age on response to palliative radiotherapy and quality of life in patients with painful bone metastases. Radiotherapy and Oncology, 2014, 111, 264-269.	0.6	20

#	Article	IF	CITATIONS
55	Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer. Critical Reviews in Oncology/Hematology, 2012, 84, 224-242.	4.4	8